Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts
Title:
Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts
Author:
Yang, J.C.-H. Ramalingam, S.S. Lee, C.K. Kurata, T. Kim, D.-W. John, T. Nogami, N. Ohe, Y. Rukazenkov, Y. Murphy, M. Jänne, P.A.